Compare Global X Defense Tech ETF (SHLD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs BIO-TECHNE Corp — how do they compare? Global X Defense Tech ETF trades at $59.92 (market cap $6.38B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Defense Tech ETF for 44 Days and BIO-TECHNE Corp for 63 Days on average.
| SHLD | TECH | |
|---|---|---|
Market Cap | $6.38B | $11.37B |
Volume | 1,280,546 | 3,153,511 |
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $72.61 |
52-Week Low | $58.20 | $43.31 |
Typical Hold Time | 44 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD (Global X Defense Tech ETF) trades at $58.74, down 2.2% on the day amid bearish technical signals. The ETF faces selling pressure with all 13 moving averages signaling bearish momentum, though oversold RSI readings at 10.99 (6-day) and 15.12 (12-day) suggest potential for near-term bounce. Recent institutional filings show increased buying interest from firms like Focus Financial Network (+55.4% stake) and Balefire LLC ($1.12M new position) in Q2 2026, indicating professional confidence in defense tech exposure.
The defense technology sector benefits from geopolitical tensions and rising global military budgets, with EU allies planning significant rearmament spending. However, the ETF's concentrated focus on emerging tech carries execution risks versus broader aerospace peers. Current technical weakness contrasts with fundamental tailwinds, creating a divergence that may resolve with either sector momentum recovery or continued ETF-specific pressure.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
